https://casr-signal.com/the-fu....nction-of-f0-and-pho
In spite of recent advances in neoadjuvant chemo-immunotherapy, all patients do not uniformly respond well to the combined regimen of ICIs and chemotherapy, potentially causing significant immune-related adverse effects (irAEs). A similar approach to patient selection for targeted therapies, identifying patients who are most likely to respond positively to chemo-immunotherapy, is of great value. In recent medical literature, a number of prognostic and predictive markers for the efficacy o
Like
Comment
Share
